Advertisement

Drug Safety

pp 1–11 | Cite as

Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

  • Lauren Pavlik
  • Arie RegevEmail author
  • Paul A. Ardayfio
  • Naga P. Chalasani
Review Article

Abstract

Drug-induced steatosis (DIS) and drug-induced steatohepatitis (DISH) are two of several types of drug-induced liver injury (DILI). They can be caused by various drugs and may present as acute, potentially lethal disorders or as chronic slowly progressive liver injury. Despite the fact that they are distinct disorders, the slow progressive forms of DIS and DISH are often confused with or misdiagnosed as non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), which are much more common and, by definition, not caused by drugs. Currently the only way to identify DIS is via imaging studies or a liver biopsy, while DISH can be identified only through liver biopsy. In addition, diagnosis of either DIS or DISH requires an exhaustive clinical evaluation and comprehensive causality assessment to rule out other possible causes and determine the association with the suspected drug. Furthermore, it is difficult, using existing methods, to monitor the progression of DIS and DISH and to determine the underlying mechanism. Therefore, there is a great unmet need for non-invasive biomarkers that will be able to identify the development of DIS or DISH during drug development and to monitor for progression or regression of the disorder during treatment or following drug discontinuation. Recent developments in the fields of NAFLD and NASH have introduced several novel biomarkers that show promise for the diagnosis, monitoring, and severity assessment of these common diseases. Given the significant overlap in possible underlying mechanisms and histological pattern between NAFLD/NASH and DIS/DISH, these postulated NAFLD and NASH biomarkers may have a potential application to DIS and DISH. This article reviews the existing medical literature and other publically available information pertaining to novel serum biomarkers for NAFLD and NASH, and explores the concurrent identification of these biomarkers for DIS and DISH.

Notes

Acknowledgements

The authors thank Natasha Cole for her help in the preparation of this review paper.

Compliance with Ethical Standards

Conflict of interest

Dr. Lauren Pavlik has no conflicts of interest related to this paper. Dr. Naga Chalasani serves as a consultant to several pharmaceutical companies for activities related to NAFLD and DILI, but has no conflicts of interest that are directly relevant to the content of this paper. Dr. Arie Regev and Dr. Paul Ardayfio are full-time employees of Eli Lilly, but have no conflicts of interest that are directly relevant to the content of this paper.

Funding

No sources of funding were used to assist in the preparation of this study.

References

  1. 1.
    Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.CrossRefGoogle Scholar
  2. 2.
    Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.CrossRefGoogle Scholar
  3. 3.
    Rabinowich L, Shibolet O. Drug induced steatohepatitis: an uncommon culprit of a common disease. Biomed Res Int. 2015;2015:168905.CrossRefGoogle Scholar
  4. 4.
    Barsic N, Lerotic I, Smircic-Duvnjak L, Tomasic V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol. 2012;18(30):3945–54.CrossRefGoogle Scholar
  5. 5.
    Amacher DE. Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease. Biomarkers. 2014;19(7):541–52.CrossRefGoogle Scholar
  6. 6.
    Amacher DE. Strategies for the early detection of drug-induced hepatic steatosis in preclinical drug safety evaluation studies. Toxicology. 2011;279(1–3):10–8.CrossRefGoogle Scholar
  7. 7.
    Dash A, Figler RA, Sanyal AJ, Wamhoff BR. Drug-induced steatohepatitis. Expert Opin Drug Metab Toxicol. 2017;13(2):193–204.CrossRefGoogle Scholar
  8. 8.
    National Institute of Health. LiverTox: phenotypes of drug induced liver injury; 2016. https://www.livertox.nih.gov/Phenotypes_intro.html. Accessed 25 Oct 2018.
  9. 9.
    Amacher DE, Chalasani N. Drug-induced hepatic steatosis. Semin Liver Dis. 2014;34(2):205–14.CrossRefGoogle Scholar
  10. 10.
    Satapathy SK, Kuwajima V, Nadelson J, Atiq O, Sanyal AJ. Drug-induced fatty liver disease: an overview of pathogenesis and management. Ann Hepatol. 2015;14(6):789–806.CrossRefGoogle Scholar
  11. 11.
    Fromenty B, Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther. 1995;67(1):101–54.CrossRefGoogle Scholar
  12. 12.
    Madrazo BL. Diagnosis of nonalcoholic steatohepatitis without liver biopsy. Gastroenterol Hepatol. 2017;13(6):378–80.Google Scholar
  13. 13.
    Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology. 2017;152(3):598–607.e2.CrossRefGoogle Scholar
  14. 14.
    Angulo P. GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2007;25(8):883–9.CrossRefGoogle Scholar
  15. 15.
    Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134(6):1682–98.CrossRefGoogle Scholar
  16. 16.
    Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100.CrossRefGoogle Scholar
  17. 17.
    Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, et al. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000;33(5):716–24.CrossRefGoogle Scholar
  18. 18.
    Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145(4):782-9.e4.CrossRefGoogle Scholar
  19. 19.
    Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–12.CrossRefGoogle Scholar
  20. 20.
    Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M, et al. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice–an exploratory case-control study. PLoS One. 2014;9(10):e111551.CrossRefGoogle Scholar
  21. 21.
    Maximos M, Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Biernacki D, et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology. 2015;61(1):153–60.CrossRefGoogle Scholar
  22. 22.
    Vuppalanchi R, Jain AK, Deppe R, Yates K, Comerford M, Masuoka HC, et al. Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2121–30.e1-2.Google Scholar
  23. 23.
    Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013;33(9):1398–405.CrossRefGoogle Scholar
  24. 24.
    Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005;42(3):650–6.CrossRefGoogle Scholar
  25. 25.
    Miyazaki, Miwa S, Kodama H, Yamada H, Nagata K, Toriumi W, et al. Hepatic and intestinal changes in rats treated with T-0126, a microsomal triglyceride transfer protein (mtp) inhibitor. J Toxicol Sci. 2007;32(2):161–77.Google Scholar
  26. 26.
    Stein EA, Dufour R, Gagne C, Gaudet D, East C, Donovan JM, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(19):2283–92.CrossRefGoogle Scholar
  27. 27.
    Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years’ treatment with lomitapide. JAMA Intern Med. 2014;174(3):443–7.CrossRefGoogle Scholar
  28. 28.
    Blom DJ, Averna MR, Meagher EA, du Toit Theron H, Sirtori CR, Hegele RA, et al. Long-term efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in patients with homozygous familial hypercholesterolemia. Circulation. 2017;136(3):332–5.CrossRefGoogle Scholar
  29. 29.
    Murata Y, Ogawa Y, Saibara T, Nishioka A, Fujiwara Y, Fukumoto M, et al. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep. 2000;7(6):1299–304.Google Scholar
  30. 30.
    Church RJ, Watkins PB. The transformation in biomarker detection and management of drug-induced liver injury. Liver Int. 2017;37(11):1582–90.CrossRefGoogle Scholar
  31. 31.
    Wruck W, Graffmann N, Kawala MA, Adjaye J. Concise review: current status and future directions on research related to nonalcoholic fatty liver disease. Stem Cells. 2017;35(1):89–96.CrossRefGoogle Scholar
  32. 32.
    He L, Deng L, Zhang Q, Guo J, Zhou J, Song W, et al. Diagnostic value of CK-18, FGF-21, and related biomarker panel in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Biomed Res Int. 2017;2017:9729107.Google Scholar
  33. 33.
    Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24(4):564–8.CrossRefGoogle Scholar
  34. 34.
    Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology.  https://doi.org/10.1002/hep.29802 (Epub 2018 Jan 22).
  35. 35.
    Clarke JI, Dear JW, Antoine DJ. Recent advances in biomarkers and therapeutic interventions for hepatic drug safety—false dawn or new horizon? Expert Opin Drug Saf. 2016;15(5):625–34.Google Scholar
  36. 36.
    Robles-Diaz M, Medina-Caliz I, Stephens C, Andrade RJ, Lucena MI. Biomarkers in DILI: one more step forward. Front Pharmacol. 2016;7:267.CrossRefGoogle Scholar
  37. 37.
    FDA, CDER. Application number 203858Orig1s000. Other reviews. Mipomersen and lomitapide consultation; 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/203858Orig1s000OtherR.pdf. Accessed 25 Oct 2018.
  38. 38.
    Amryt Pharmaceuticals DAC. Lojuxta: EPAR- product information; 2018. https://www.ema.europa.eu/documents/product-information/lojuxta-epar-product-information_en.pdf. Accessed 25 Oct 2018.
  39. 39.
    Wu G, Li H, Fang Q, Zhang J, Zhang M, Zhang L, et al. Complementary role of fibroblast growth factor 21 and cytokeratin 18 in monitoring the different stages of nonalcoholic fatty liver disease. Sci Rep. 2017;7(1):5095.CrossRefGoogle Scholar
  40. 40.
    Yan H, Xia M, Chang X, Xu Q, Bian H, Zeng M, et al. Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a cross-sectional study. PLoS One. 2011;6(9):e24895.CrossRefGoogle Scholar
  41. 41.
    Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 2010;53(5):934–40.CrossRefGoogle Scholar
  42. 42.
    Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest. 2010;40(10):887–92.CrossRefGoogle Scholar
  43. 43.
    Sahini N, Selvaraj S, Borlak J. Whole genome transcript profiling of drug induced steatosis in rats reveals a gene signature predictive of outcome. PLoS One. 2014;9(12):e114085.CrossRefGoogle Scholar
  44. 44.
    Gariani K, Drifte G, Dunn-Siegrist I, Pugin J, Jornayvaz FR. Increased FGF21 plasma levels in humans with sepsis and SIRS. Endocr Connect. 2013;2(3):146–53.CrossRefGoogle Scholar
  45. 45.
    Hagstrom H, Stal P, Hultcrantz R, Brismar K, Ansurudeen I. IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD—a pilot study. Scand J Gastroenterol. 2017;52(12):1427–34.CrossRefGoogle Scholar
  46. 46.
    Tolosa L, Gomez-Lechon MJ, Jimenez N, Hervas D, Jover R, Donato MT. Advantageous use of HepaRG cells for the screening and mechanistic study of drug-induced steatosis. Toxicol Appl Pharmacol. 2016;302:1–9.CrossRefGoogle Scholar
  47. 47.
    Moya M, Benet M, Guzman C, Tolosa L, Garcia-Monzon C, Pareja E, et al. Foxa1 reduces lipid accumulation in human hepatocytes and is down-regulated in nonalcoholic fatty liver. PLoS One. 2012;7(1):e30014.CrossRefGoogle Scholar
  48. 48.
    Benet M, Moya M, Donato MT, Lahoz A, Hervas D, Guzman C, et al. A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch Toxicol. 2014;88(4):967–82.CrossRefGoogle Scholar
  49. 49.
    Liu XL, Cao HX, Fan JG. MicroRNAs as biomarkers and regulators of nonalcoholic fatty liver disease. J Dig Dis. 2016;17(11):708–15.CrossRefGoogle Scholar
  50. 50.
    Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, et al. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 2014;34(7):e302–7.CrossRefGoogle Scholar
  51. 51.
    Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Ledesma MMGL, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64(5):800–12.CrossRefGoogle Scholar
  52. 52.
    Wang K, Zhang S, Marzolf B, Troisch P, Brightman A, Hu Z, et al. Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA. 2009;106(11):4402–7.CrossRefGoogle Scholar
  53. 53.
    Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta. 2013;424:99–103.CrossRefGoogle Scholar
  54. 54.
    Lopez-Riera M, Conde I, Tolosa L, Zaragoza A, Castell JV, Gomez-Lechon MJ, et al. New microRNA biomarkers for drug-induced steatosis and their potential to predict the contribution of drugs to non-alcoholic fatty liver disease. Front Pharmacol. 2017;8:3.CrossRefGoogle Scholar
  55. 55.
    Liu Z, Wang Y, Borlak J, Tong W. Mechanistically linked serum miRNAs distinguish between drug induced and fatty liver disease of different grades. Sci Rep. 2016;6:23709.CrossRefGoogle Scholar
  56. 56.
    Cermelli S, Ruggieri A, Marrero JA, Ioannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One. 2011;6(8):e23937.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Eugene Applebaum College of Pharmacy and Health SciencesWayne State UniversityDetroitUSA
  2. 2.Eli Lilly and CompanyIndianapolisUSA
  3. 3.Indiana University School of MedicineIndianapolisUSA

Personalised recommendations